Novozymes A/S, trading under the Novonesis brand and listed with reference 0Q4U, has reported nine-month 2026 results showing 7% organic sales growth and an adjusted EBITDA margin of 37.9%, with the company confirming its full-year outlook of 7–8% organic sales growth and an adjusted EBITDA margin at the higher end of the 37–38% range. The biosolutions group, which operates across both food and health and planetary health markets, also completed the acquisition of the remaining 77% of MicroBioGen on 1 October 2026, securing full access to what it describes as an attractive yeast platform. Investors will note that management has indicated high-single digit organic sales growth for the fourth quarter, lending confidence to the confirmed annual guidance.

Key Points

  • Novozymes A/S (Novonesis, 0Q4U) — global biosolutions company operating across food, health, and planetary health markets
  • Nine-month 2026 organic sales growth of 7%, with Q3 standalone growth of 6%; adjusted EBITDA margin of 37.9% for the nine-month period
  • Full-year 2026 guidance confirmed: 7–8% organic sales growth and adjusted EBITDA margin at the higher end of the 37–38% range; Q4 organic growth indicated at high-single digit
  • Investors should watch the MicroBioGen integration progress, ongoing share buyback execution against the EUR 75 million programme, and Q4 trading updates

Food and Health Biosolutions Leads Growth Whilst Planetary Health Accelerates in Q3

Novonesis reported that its Food & Health Biosolutions segment grew 9% organically over the nine-month period, with Q3 alone delivering 8% growth driven by the Food & Beverages category. The segment absorbed approximately 2 percentage points of negative effect from the company's deliberate exit from certain countries. Planetary Health Biosolutions delivered 6% organic growth for the nine months, with the Q3 figure accelerating to 4% — suggesting improving momentum in that division. The announcement notes that developed markets grew 7% organically for the nine months, while emerging markets grew 6%, the latter including close to 3 percentage points of headwind from country exits.

Adjusted EBITDA Margin of 37.9% Reflects 60bps Year-on-Year Improvement Despite Currency Headwinds

The nine-month adjusted EBITDA margin of 37.9% represents a 60 basis point improvement on the prior-year comparable period, inclusive of a minor currency headwind, according to the announcement. The Q3 margin of 38.3% was 120 basis points higher than the same quarter last year. The company's net interest-bearing debt to EBITDA ratio stood at 1.7 times, and free cash flow before acquisitions represented 17% of sales. The CAPEX-to-sales ratio reached 10.2%, described in the announcement as in line with plan, indicating disciplined capital allocation across the group's biosolutions operations.

MicroBioGen Acquisition Completed and EUR 14.8 Million of Share Buyback Executed

Novonesis confirmed it completed the acquisition of the remaining 77% stake in MicroBioGen on 1 October 2026, giving the group full ownership of what the announcement describes as an attractive yeast platform, potentially broadening its scientific biosolutions capabilities. Separately, the company disclosed that as of 30 September 2026, EUR 14.8 million had been deployed under its EUR 75 million share buyback programme for 2026. Both developments may be of interest to investors monitoring capital allocation discipline alongside the group's organic growth trajectory heading into the final quarter of the financial year.